Catalio Capital Management
Catalio Capital Management is a venture capital firm founded in 2020 and based in New York, specializing in investments within the biomedical technology sector. The firm manages multiple funds, including the Catalio Access Funds and various special opportunities and credit funds. Catalio employs a diverse investment strategy that encompasses private equity, private credit, and public equity, utilizing a long bias and fundamental analysis approach. With a focus on breakthrough biomedical technologies, Catalio aims to support innovative companies in this rapidly evolving industry. Additionally, the firm is a Registered Investment Adviser, ensuring compliance with regulatory standards in its investment activities.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.